As of 2024-12-14, the EV/EBITDA ratio of Cytokinetics Inc (CYTK) is -10.59. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CYTK's latest enterprise value is 5,572.56 mil USD. CYTK's TTM EBITDA according to its financial statements is -526.15 mil USD. Dividing these 2 quantities gives us the above CYTK EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.0x | 16.0x |
| Forward P/E multiples | 15.4x - 21.2x | 15.7x |
| Fair Price | (65.65) - (72.60) | (67.65) |
| Upside | -230.7% - -244.5% | -234.7% |
| Date | EV/EBITDA |
| 2024-12-09 | -10.65 |
| 2024-12-06 | -10.75 |
| 2024-12-05 | -10.63 |
| 2024-12-04 | -10.64 |
| 2024-12-03 | -10.88 |
| 2024-12-02 | -10.68 |
| 2024-11-29 | -10.96 |
| 2024-11-27 | -11.04 |
| 2024-11-26 | -10.99 |
| 2024-11-25 | -10.59 |
| 2024-11-22 | -10.34 |
| 2024-11-21 | -10.02 |
| 2024-11-20 | -10.51 |
| 2024-11-19 | -10.78 |
| 2024-11-18 | -10.97 |
| 2024-11-15 | -10.59 |
| 2024-11-14 | -11.59 |
| 2024-11-13 | -11.88 |
| 2024-11-12 | -11.93 |
| 2024-11-11 | -12.47 |
| 2024-11-08 | -12.33 |
| 2024-11-07 | -11.85 |
| 2024-11-06 | -11.77 |
| 2024-11-05 | -11.10 |
| 2024-11-04 | -10.87 |
| 2024-11-01 | -10.95 |
| 2024-10-31 | -10.76 |
| 2024-10-30 | -10.83 |
| 2024-10-29 | -10.88 |
| 2024-10-28 | -11.05 |
| 2024-10-25 | -10.83 |
| 2024-10-24 | -11.08 |
| 2024-10-23 | -11.22 |
| 2024-10-22 | -11.65 |
| 2024-10-21 | -11.39 |
| 2024-10-18 | -11.65 |
| 2024-10-17 | -11.55 |
| 2024-10-16 | -11.72 |
| 2024-10-15 | -11.75 |
| 2024-10-14 | -11.55 |
| 2024-10-11 | -11.63 |
| 2024-10-10 | -11.25 |
| 2024-10-09 | -11.53 |
| 2024-10-08 | -11.51 |
| 2024-10-07 | -11.77 |
| 2024-10-04 | -12.04 |
| 2024-10-03 | -11.82 |
| 2024-10-02 | -11.12 |
| 2024-10-01 | -11.12 |
| 2024-09-30 | -11.17 |